GenMont Biotech Inc (3164) - Total Assets

Latest as of March 2026: NT$1.70 Billion TWD ≈ $53.65 Million USD

Based on the latest financial reports, GenMont Biotech Inc (3164) holds total assets worth NT$1.70 Billion TWD (≈ $53.65 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

GenMont Biotech Inc - Total Assets Trend (2003–2025)

This chart illustrates how GenMont Biotech Inc's total assets have evolved over time, based on quarterly financial data. Also see GenMont Biotech Inc stock valuation for the company's overall valuation and market capitalisation.

GenMont Biotech Inc - Asset Composition Analysis

Current Asset Composition (December 2025)

GenMont Biotech Inc's total assets of NT$1.70 Billion consist of 33.4% current assets and 66.7% non-current assets. Review 3164 total debt and obligations to assess the company's total debt and financial obligations.

Asset Category	Amount (TWD)	% of Total Assets
Cash & Equivalents	NT$0.00	6.2%
Accounts Receivable	NT$46.89 Million	2.8%
Inventory	NT$70.39 Million	4.2%
Property, Plant & Equipment	NT$0.00	0.0%
Intangible Assets	NT$2.01 Million	0.1%
Goodwill	NT$0.00	0.0%

Asset Composition Trend (2003–2025)

This chart illustrates how GenMont Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See GenMont Biotech Inc share price for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: GenMont Biotech Inc's current assets represent 33.4% of total assets in 2025, an increase from 0.0% in 2003.
Cash Position: Cash and equivalents constituted 6.2% of total assets in 2025, up from 2.5% in 2003.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 10.0% in 2003.
Asset Diversification: The largest asset category is inventory at 4.2% of total assets.

GenMont Biotech Inc Competitors by Total Assets

Key competitors of GenMont Biotech Inc based on total assets are shown below.

Company	Country	Total Assets
CSL Ltd AU:CSL	Australia	AU$39.54 Billion
Vaxcyte Inc NASDAQ:PCVX	USA	$3.14 Billion
Bachem Holding AG SW:BANB	Switzerland	CHF2.11 Billion
Definium Therapeutics, Inc. NASDAQ:DFTX	USA	$1.11 Billion
Chongqing Zhifei Bio Products SHE:300122	China	CN¥29.09 Billion
HLB Co. Ltd KQ:028300	Korea	₩925.44 Billion
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	China	CN¥6.82 Billion
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	China	CN¥3.16 Billion

GenMont Biotech Inc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.77	2.58	5.27
Quick Ratio	2.44	2.24	4.97
Cash Ratio	0.00	0.00	0.00
Working Capital	NT$369.77 Million	NT$350.25 Million	NT$470.62 Million

GenMont Biotech Inc - Advanced Valuation Insights

This section examines the relationship between GenMont Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.07
Latest Market Cap to Assets Ratio	0.03
Asset Growth Rate (YoY)	-2.6%
Total Assets	NT$1.67 Billion
Market Capitalization	$42.95 Million USD

Valuation Analysis

Below Book Valuation: The market values GenMont Biotech Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: GenMont Biotech Inc's assets decreased by 2.6% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for GenMont Biotech Inc (2003–2025)

The table below shows the annual total assets of GenMont Biotech Inc from 2003 to 2025.

Year	Total Assets	Change
2025-12-31	NT$1.67 Billion ≈ $52.46 Million	-2.56%
2024-12-31	NT$1.71 Billion ≈ $53.83 Million	+3.36%
2023-12-31	NT$1.65 Billion ≈ $52.08 Million	-2.51%
2022-12-31	NT$1.70 Billion ≈ $53.43 Million	-0.13%
2021-12-31	NT$1.70 Billion ≈ $53.50 Million	+5.28%
2020-12-31	NT$1.61 Billion ≈ $50.81 Million	+2.65%
2019-12-31	NT$1.57 Billion ≈ $49.50 Million	-5.26%
2018-12-31	NT$1.66 Billion ≈ $52.25 Million	+10.54%
2017-12-31	NT$1.50 Billion ≈ $47.26 Million	+6.87%
2016-12-31	NT$1.40 Billion ≈ $44.23 Million	-14.08%
2015-12-31	NT$1.63 Billion ≈ $51.47 Million	-6.21%
2014-12-31	NT$1.74 Billion ≈ $54.88 Million	+26.81%
2013-12-31	NT$1.37 Billion ≈ $43.28 Million	-3.81%
2012-12-31	NT$1.43 Billion ≈ $45.00 Million	-4.33%
2011-12-31	NT$1.49 Billion ≈ $47.03 Million	+9.32%
2010-12-31	NT$1.37 Billion ≈ $43.02 Million	+88.58%
2009-12-31	NT$724.10 Million ≈ $22.81 Million	+6.34%
2008-12-31	NT$680.96 Million ≈ $21.45 Million	+19.11%
2007-12-31	NT$571.68 Million ≈ $18.01 Million	+9.74%
2006-12-31	NT$520.93 Million ≈ $16.41 Million	+66.14%
2005-12-31	NT$313.55 Million ≈ $9.88 Million	+1.45%
2004-12-31	NT$309.07 Million ≈ $9.74 Million	+19.67%
2003-12-31	NT$258.26 Million ≈ $8.14 Million	--

About GenMont Biotech Inc

TW:3164 Taiwan Biotechnology

Market Cap

$42.95 Million

NT$1.36 Billion TWD

Market Cap Rank

#22550 Global

#1385 in Taiwan

Share Price

NT$15.85

Change (1 day)

+0.96%

52-Week Range

NT$15.60 - NT$19.70

All Time High

NT$30.54